Quantum Genesis AI Corp. (OTC: QGAI) has issued a clarification regarding its research activities and intellectual property, aiming to distinguish the company from Quantumzyme LLP, a separate entity based in Bengaluru, India. The announcement follows prior press releases that referenced scientific publications in the enzyme engineering and biocatalysis field, which listed Quantumzyme LLP and its researchers as authors.
The company, focused on enzyme engineering, molecular modeling, and biocatalysis, clarified that Quantumzyme LLP is not a subsidiary or affiliate. However, it emphasized that certain intellectual property and technology rights were transferred to Quantum Genesis AI via an Asset Purchase Agreement dated February 21, 2023, and a subsequent confirmatory assignment disclosed in a Form 8-K filed on April 29, 2026.
According to the statement, the company’s Chief Executive Officer, Naveen Kulkarni, transferred to the company core intellectual property, know-how, methodologies, and research materials associated with its enzyme engineering and biocatalysis business. The company believes that research activities conducted by Mr. Kulkarni, whether directly or through Quantumzyme LLP, that relate to the company’s core field and are based on or derived from the transferred technology platform fall within the scope of the rights transferred to the company.
This clarification is significant for investors and stakeholders as it addresses potential confusion about the ownership of key technologies and research outputs. The company’s prior disclosures referencing scientific publications were based on its ownership of the relevant intellectual property. By distinguishing Quantumzyme LLP from Quantum Genesis AI, the company aims to provide transparency regarding the origins of its technology and the affiliations of its researchers.
Quantum Genesis AI Corp. is advancing technologies at the intersection of artificial intelligence, computational modeling, and scientific innovation. The company leverages data-driven tools to support research and discovery across emerging sectors. For more information, visit qgaicorp.com and the company’s profile at otcmarkets.com/stock/QGAI.
The company’s statement underscores the importance of understanding the scope of its intellectual property rights, which are central to its business strategy and value proposition. As the company continues to develop its enzyme engineering platform, clarity on IP ownership will be crucial for investors evaluating its technology assets and competitive position.
